Plain-English translation of NCT06700096 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia B research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new gene therapy called arvenacogene sanparvovec for men with hemophilia B, a bleeding disorder caused by low levels of a clotting factor. The study will compare how well the medication works and how safe it is, tracking participants for up to 5 years after treatment. Researchers hope this therapy could reduce or eliminate the need for regular clotting factor infusions.
Men with hemophilia B currently need frequent injections of clotting factor to prevent serious bleeding episodes and stay healthy. This trial is exploring whether a one-time gene therapy treatment could work longer-lasting and reduce the burden of ongoing treatment.
You likely qualify if…
You likely don't qualify if…
You will first enter a 6-month observation period where you continue your regular clotting factor treatments as usual—researchers are simply tracking how often you bleed and how much treatment you need. After that, you'll receive a single infusion of the new gene therapy medication. Then you'll have visits over the next 18 months to monitor how well it's working, followed by follow-up visits for up to 5 years total to ensure the treatment remains safe and effective.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Russia